Tezspire approved for self-administration in the EU in a new pre-filled pen
New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZenecas Tezspire has received a positive opinion from the... | January 13, 2023
United Kingdom United States Lymphopoietin Isoforms Ian Pavord Astrazeneca Tezspire Tezepelumab Pharmacokinetics
Source: marketscreener.com